

編號	成分名	參考適應症	藥物分類	藥物名冊分類*	適應症資料來源	備註
1	Rufinamide	- 輔助雷葛氏症候群引起的癲癇；LGS	中樞神經系統藥物	專用藥物	MIMS HK	
2	Eculizumab	- 非典型溶血性尿毒症候群；aHUS	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	安全網藥物 (關愛基金)
3	Interferon-Gamma 1b	- 慢性肉芽腫疾病	癌瘤及免疫系統藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
4	Eltrombopag	- 慢性免疫性血小板減少性紫癜 - 重度再生障礙性貧血；SAA	營養劑及血液科藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
5	Canakinumab	- Cryopyrin 相關周期性綜合症；CAPS	肌肉骨骼和關節疾病藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
6	Pasireotide	- 庫欣病 / 肢端肥大症	癌瘤及免疫系統藥物	專用藥物	MIMS HK	
7	Tobramycin	- 囊腫性纖維化	眼科藥物	通用藥物	MIMS HK	
8	Growth Hormone	- 侏儒症	內分泌系統藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
9	Aqalsidase Alfa	- 法布瑞氏症	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	專用藥物
10	Aqalsidase Beta	- 法布瑞氏症	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	專用藥物
11	Imiglucerase	- 高壽氏症	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	專用藥物
12	Icatibant	- 遺傳性血管性水腫；HAE	呼吸系統藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
13	Tafamidis	- 遺傳性轉甲狀腺素蛋白類澱粉沉著症造成之心肌病變；ATTR-CM	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	安全網藥物 (關愛基金)
14	Evolocumab	- 同合子家族性高膽固醇血症；HoFH	心臟科藥物	專用藥物	MIMS HK	
15	Nintedanib	- 特發性肺纖維化；IPF	呼吸系統藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
16	Nusinersen	- 嬰兒期 / 兒童期發病型脊髓肌肉萎縮症；SMA	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	安全網藥物 (關愛基金)
17	Tocilizumab	- 幼年特發性關節炎 - 全身性幼年特發性關節炎	肌肉骨骼和關節疾病藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
18	Laronidase	- 黏多醣症第1型	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	專用藥物
19	Idursulfase	- 黏多醣症第2型	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	專用藥物
20	Elosulfase Alfa	- 黏多醣症第4A型	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	專用藥物
21	Galsulfase	- 黏多醣症第6型	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	專用藥物
22	Adalimumab	- 活性、非感染性、中段 / 後段 / 葡萄膜炎 - 小兒慢性非感染性葡萄膜炎 - 幼年特發性關節炎	眼科藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
23	Tisagenlecleucel	- 用於治療年齡為 25 歲或以下的復發或難治性 B 細胞急性淋巴瘤細胞性白血病患者 / 兩種或以上全身系統性療程後復發或難治性的瀰漫性大型 B 細胞淋巴瘤的成年患者	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	安全網藥物 (關愛基金)
24	Risedronate	- 原發性變形性骨炎	內分泌系統藥物	專用藥物	MIMS HK	
25	Eculizumab	- 陣發性夜間血紅素尿症；PNH	NA	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
26	Alglucosidase Alfa	- 龐貝氏症	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	專用藥物
27	Epoprostenol	- 原發性肺動脈高血壓	心臟科藥物	通用藥物	MIMS HK	
28	Ambriasantan	- 原發性肺動脈高血壓	心臟科藥物	專用藥物	MIMS HK	
29	Bosentan	- 肺動脈高壓；PAH	心臟科藥物	專用藥物	MIMS HK	
30	Ilprost	- 肺動脈高壓；PAH	心臟科藥物	專用藥物	MIMS HK	
31	Macitentan	- 肺動脈高壓；PAH	心臟科藥物	專用藥物	MIMS HK	
32	Selexipaq	- 肺動脈高壓；PAH	心臟科藥物	專用藥物	MIMS HK	
33	Sildenafil citrate	- 肺動脈高壓；PAH	心臟科藥物	專用藥物	MIMS HK	
34	Interferon-Beta	- 多發性硬化症；MS	癌瘤及免疫系統藥物	專用藥物	MIMS HK	
35	Alemtuzumab	- 復發緩解型多發性硬化症；RRMS	癌瘤及免疫系統藥物	專用藥物	MIMS HK	
36	Cladribine	- 復發緩解型多發性硬化症；RRMS	癌瘤及免疫系統藥物	專用藥物	MIMS HK	
37	Dimethyl fumarate	- 復發緩解型多發性硬化症；RRMS	癌瘤及免疫系統藥物	專用藥物	MIMS HK	
38	Fingolimod	- 復發緩解型多發性硬化症；RRMS	癌瘤及免疫系統藥物	專用藥物	MIMS HK	
39	Natalizumab	- 復發緩解型多發性硬化症；RRMS	癌瘤及免疫系統藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
40	Teriflunomide	- 成人復發緩解型多發性硬化症；RRMS	癌瘤及免疫系統藥物	專用藥物	MIMS HK	
41	Siponimod	- 次發進展型多發性硬化症；SPMS	癌瘤及免疫系統藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
42	Everolimus	- 結節性硬化症相關腎血管平滑肌脂肪瘤；TSC - 與結節性硬化症相關的室管膜下鉅細胞星形細胞瘤；TSC - 輔助治療與結節性硬化症相關的難治性部分性癲癇；TSC	癌瘤及免疫系統藥物	專用藥物	MIMS HK	根據不同的適應症，該藥物已被列入專用藥物、安全網 (撒瑪利亞基金) 和自費項目。
43	Rituximab	- 非致命活性及嚴重肉芽腫性血管炎或顯微多發性血管炎	風濕病學藥物	自費藥物	醫管局網頁	安全網藥物 (撒瑪利亞基金)
44	Deferiprone (Kelfer)	- 重型地中海貧血症	營養劑及血液科藥物	專用藥物	MIMS HK	
45	Dinutuximab Beta	- 治療高風險或復發 / 難治的神經母細胞瘤	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	安全網藥物 (關愛基金)
46	Tafamidis Meqlumine	- TTR-家族性澱粉樣多發性神經病變；TTR-FAP	NA	個別病人特別用藥計劃 - 極度昂貴藥物名單	醫管局網頁	安全網藥物 (關愛基金)
47	Penicillamine	- 威爾遜氏症	肌肉骨骼和關節疾病藥物	通用藥物	MIMS HK	
48	Zinc Acetate	- 威爾遜氏症	營養劑及血液科藥物	通用藥物	FDA	

醫院管理局《藥物名冊》分類*	
通用藥物	經證實對病人有關臨床情況適用和有效，並可供一般使用的藥物。公立醫院和診所提供這類藥物時，會收取標準費用。
專用藥物	在特定臨床應用下經專科醫生特別授權使用的藥物。如這類藥物是在特定的臨床應用下處方，公立醫院和診所會收取標準費用。如個別病人在特定臨床應用以外選擇使用專用藥物，便需自行支付藥物的費用。
獲安全網資助的自費購買藥物 (自費藥物)	經證實有顯著療效，但超出醫管局一般資助服務範圍所能提供的非常昂貴藥物。這些藥物不屬公立醫院和診所標準收費提供的項目。需要使用這些藥物而有能力負擔費用的病人須自費購買。然而，相關基金會為需要這些藥物而經濟上有困難的病人提供安全網。
不獲安全網資助的自費藥物	僅經初步醫療驗證的藥物、與其他替代藥物相比僅具邊緣效益，但成本明顯昂貴的藥物，以及生活方式藥物(例如減肥藥)。這些藥物並不會包括在標準收費範圍內，病人需自費購買。
*資料來源：醫管局藥物名冊網頁	

No.	Ingredients	Reference Indication	By BNF Therapeutic Class	Drug Formulary Category*	Indication Source	Remarks
1	Rufinamide	- Adjunct for seizures associated with the Lennox-Gastaut syndrome · LGS	Central Nervous System	Special Drugs	MIMS HK	
2	Eculizumab	- Atypical Hemolytic Uremic Syndrome · aHUS	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Safety Net (Community Care Fund)
3	Interferon-Gamma 1b	- Chronic Granulomatous Disease	Malignant Disease and Immunosuppression	Self-financed item	HA Website	Safety Net (Samaritan Fund)
4	Eltrombopag	- Chronic immune thrombocytopenia - Severe aplastic anaemia · SAA	Nutrition and Blood	Self-financed item	HA Website	Safety Net (Samaritan Fund)
5	Canakinumab	- Cryopyrin-associated periodic syndromes · CAPS	Musculoskeletal and Joint Diseases	Self-financed item	HA Website	Safety Net (Samaritan Fund)
6	Pasireotide	- Cushing's disease / Acromegaly	Malignant Disease and Immunosuppression	Special Drugs	MIMS HK	
7	Tobramycin	- Cystic Fibrosis	Eye	General Drugs	MIMS HK	
8	Growth Hormone	- Dwarfism	Endocrine System	Self-financed item	HA Website	Safety Net (Samaritan Fund)
9	Agalsidase Alfa	- Fabry Disease	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Special Drugs
10	Agalsidase Beta	- Fabry Disease	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Special Drugs
11	Imiglucerase	- Gaucher's Disease	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Special Drugs
12	Icatibant	- Hereditary angioedema · HAE	Respiratory System	Self-financed item	HA Website	
13	Tafamidis	- Hereditary Transthyretin Amyloidosis with Cardiomyopathy	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Safety Net (Community Care Fund)
14	Evolocumab	- Homozygous Familial Hypercholesterolemia · HoFH	Cardiovascular System	Special Drugs	MIMS HK	
15	Nintedanib	- Idiopathic Pulmonary Fibrosis · IPF	Respiratory System	Self-financed item	HA Website	Safety Net (Samaritan Fund)
16	Nusinersen	- Infantile / Childhood Onset Spinal Muscular Atrophy (SMA)	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Safety Net (Community Care Fund)
17	Tocilizumab	- Juvenile Idiopathic Arthritis - Systemic juvenile idiopathic arthritis	Musculoskeletal and Joint Diseases	Self-financed item	HA Website	Safety Net (Samaritan Fund)
18	Laronidase	- Mucopolysaccharidosis I	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Special Drugs
19	Idursulfase	- Mucopolysaccharidosis II	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Special Drugs
20	Elosulfase Alfa	- Mucopolysaccharidosis IVA	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Special Drugs
21	Galsulfase	- Mucopolysaccharidosis VI	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Special Drugs
22	Adalimumab	- Non-infectious intermediate, posterior and panuveitis - Paediatric chronic non-infectious anterior uveitis - Juvenile idiopathic arthritis	Eye	Self-financed item	HA Website	Safety Net (Samaritan Fund)
23	Tisagenlecleucel	- Paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia that is refractory · in relapse posttransplant or in second or later relapse / Adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Safety Net (Community Care Fund)
24	Risedronate	- Paget's disease of bone	Endocrine System	Special Drugs	MIMS HK	
25	Eculizumab	- Paroxysmal nocturnal hemoglobinuria · PNH		Self-financed item	HA Website	Safety Net (Samaritan Fund)
26	Alglucosidase Alfa	- Pompe Disease	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Special Drugs
27	Epoprostenol	- Primary Pulmonary Hypertension	Cardiovascular System	General Drugs	MIMS HK	
28	Ambrisentan	- Primary Pulmonary Hypertension	Cardiovascular System	Special Drugs	MIMS HK	
29	Bosentan	- Pulmonary Arterial Hypertension · PAH	Cardiovascular System	Special Drugs	MIMS HK	
30	Iloprost	- Pulmonary Arterial Hypertension · PAH	Cardiovascular System	Special Drugs	MIMS HK	
31	Macitentan	- Pulmonary Arterial Hypertension · PAH	Cardiovascular System	Special Drugs	MIMS HK	
32	Selexipag	- Pulmonary Arterial Hypertension · PAH	Cardiovascular System	Special Drugs	MIMS HK	
33	Sildenafil citrate	- Pulmonary Arterial Hypertension · PAH	Cardiovascular System	Special Drugs	MIMS HK	
34	Interferon-Beta	- Multiple Sclerosis · MS	Malignant Disease and Immunosuppression	Special Drugs	MIMS HK	

35	Alemtuzumab	- Relapsing forms of multiple sclerosis · RRMS	Malignant Disease and Immunosuppression	Special Drugs	MIMS HK	
36	Ciadribine	- Relapsing forms of multiple sclerosis · RRMS	Malignant Disease and Immunosuppression	Special Drugs	MIMS HK	
37	Dimethyl fumarate	- Relapsing forms of multiple sclerosis · RRMS	Malignant Disease and Immunosuppression	Special Drugs	MIMS HK	
38	Fingolimod	- Relapsing forms of multiple sclerosis · RRMS	Malignant Disease and Immunosuppression	Special Drugs	MIMS HK	
39	Natalizumab	- Relapsing forms of multiple sclerosis · RRMS	Malignant Disease and Immunosuppression	Self-financed item	HA Website	Safety Net (Samaritan Fund)
40	Teriflunomide	- Relapsing remitting multiple sclerosis in adults · RRMS	Malignant Disease and Immunosuppression	Special Drugs	MIMS HK	
41	Siponimod	- Secondary progressive multiple sclerosis · SPMS	Malignant Disease and Immunosuppression	Self-financed item	HA Website	Safety Net (Samaritan Fund)
42	Everolimus	- Renal angiomyolipoma associated with tuberous sclerosis complex · TSC - Subependymal giant cell astrocytoma associated with tuberous sclerosis complex · TSC	Malignant Disease and Immunosuppression	Special Drugs	MIMS HK	Based on different indication, this drug had been listed on both special drugs, safety net (Samaritan Fund) and Self-financed item.
43	Rituximab	- Severe, active non-life-threatening granulomatosis with polyangiitis / microscopic polyangiitis	Malignant Disease and Immunosuppression	Self-financed item	HA Website	Safety Net (Samaritan Fund)
44	Deferiprone (Kelfer)	- Thalassemia Major	Nutrition and Blood	Special Drugs	MIMS HK	
45	Dinutuximab Beta	- Treatment of high-risk or relapse/refractory neuroblastoma	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Safety Net (Community Care Fund)
46	Tafamidis Meglumine	- TTR-Familial Amyloidotic Polyneuropathy · TTR-FAP	NA	Special Programmes on Ultra-Expensive Drugs for Use on Individual Patient	HA Website	Safety Net (Community Care Fund)
47	Penicillamine	- Wilson's Disease	Musculoskeletal and Joint Diseases	General Drugs	MIMS HK	
48	Zinc Acetate	- Wilson's Disease	Nutrition and Blood	General Drugs	FDA	

**Hospital Authority "Drug Formulary" categories\***

General Drugs

These are drugs with well-established indications and cost-effectiveness which are available for general use as indicated by patients with relevant clinical conditions and provided at standard fees and charges in public hospitals and clinics.

Special Drugs

These are drugs used under specific clinical conditions with specific specialist authorisation. Special drugs are provided at standard fees and charges in public hospitals and clinics when prescribed under specific clinical conditions. Patients who do not meet the specified clinical conditions but choose to use Special drugs are

Self-financed Items (SFIs) with Safety Net

These are drugs which are proven to be of significant clinical benefits but are very expensive for HA to provide as part of its standard services. These drugs are not covered by the standard fees and charges in public hospitals and clinics. Patients who require these drugs and can afford the costs have to purchase the drugs at their own expense. A safety net is provided through relevant funds to subsidize the drug expenses of patients who have financial difficulties.

SFIs without Safety Net

These include drugs with preliminary medical evidence only, drugs with marginal benefits over available alternatives but at significant higher costs, and lifestyle drugs (e.g. anti-obesity drugs). These drugs are not provided as part of HA's standard services nor covered by the standard fees and charges in public hospitals and clinics. Patients who choose to use these drugs must purchase them at their own expense.

\*Reference: HA Drug Formulary Website